

*PCT
Receipt*

Docket No.: PF-0572 USN



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
Date: September 4, 2003.

By: Nancy Ramos

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang et al.

Title: HUMAN CELL SIGNALING PROTEINS (CSIG)

Serial No.: 09/763,335 Filing Date: October 15, 2001

Examiner: To Be Assigned Group Art Unit: 1646

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard; and
2. Request for Corrected Filing Receipt (2pgs);
3. Official Filing Receipt (with red-lined markings)(2pgs);
4. Copy of First Page of Published Application showing Priority Data and related Application Data;
5. Copy of Notification Relating to Priority Claim(2pg).

The fee has been calculated as shown below.

 No additional Fee is required. Fee for Petition for Extension of Time Under 37 CFR - Mo(s). \$ Please charge Deposit Account No. 09-0108 in the amount of : \$

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE CORPORATION

Diana Hamlet-Cox
Reg. No. 33,302
Direct Dial Telephone: (650) 845-4639

Date: September 4, 2003

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
on September 9, 2003.

By: Nancy Ramos

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang et al.

Title: HUMAN CELL SIGNALING PROTEINS (CSIG)

Serial No.: 09/763,335 Filing Date: October 15, 2001

Examiner: To Be Assigned Group Art Unit: 1646

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR A CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the Official Filing Receipt (with red-line markings to note changes) received from the United States Patent and Trademark Office (USPTO) in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:

- Under the Section entitled, "Applicant(s)" please Add -- Karl J. Guebler, Menlo Park, CA --;
- Under the Section entitled, "Domestic Priority data as claimed by applicant," please Add,
-- which claims benefit of 60/183,054 08/21/1998 ABN --;


Applicants hereby request that the above corrections be entered based on the following enclosed documents:

1. A copy of First Page of Published Application showing Priority data and related Application Data.
2. Copy of Notification Relating to Priority Claim

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

Respectfully submitted,
INCYTE CORPORATION

Date: September 4, 2003



Diana Hamlet-Cox
Reg. No. 33,302
Direct Dial Telephone: (650) 845-4639

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE RECD	ATTY/DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/763,335	10/15/2001	1646	990	PF-0572 USN	2	20	2

CONFIRMATION NO. 5450

Legal Department
Incyte Genomics
3160 Porter Drive
Palo Alto, CA 94304



Incyte Genomics Inc.
Patient/Corp. Legal Dept.
Received

FILING RECEIPT



MAY 21 2003

OC000000009944855

Date Mailed: 05/15/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Y. Tom Tang, San Jose, CA;
Neil C. Corley, Castro Valley, CA;
Chandra Patterson, Menlo Park, CA; -- KARL J. GUEGLER, MENLO PARK, CA; --
Mariah R Baughn, San Leandro, CA;

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US99/19072 08/19/1999
which claims benefit of 60/150,689 08/21/1998 ABN

-- WHICH CLAIMS benefit of 60/183,054 08/21/1998 ABN --

Foreign Applications

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Human cell signaling proteins (csig)

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:		(11) International Publication Number:	WO 00/11169
C12N 15/12, C07K 14/475, A61K 38/18, C07K 16/22, C12N 15/11, C12Q 1/68	A2	(43) International Publication Date:	2 March 2000 (02.03.00)
(21) International Application Number:	PCT/US99/19072	GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US).	
(22) International Filing Date:	19 August 1999 (19.08.99)		
(30) Priority Data:	60/150,689 21 August 1998 (21.08.98) US 09/137,578 21 August 1998 (21.08.98) US		(74) Agents: BILLINGS, Lucy, J. et al.; INCYTE PHARMACEUTICALS, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications	US 09/137,578 (CIP) Filed on 21 August 1998 (21.08.98) US 60/150,689 (CIP) Filed on 21 August 1998 (21.08.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US).			
(54) Title: HUMAN CELL SIGNALING PROTEINS (CSIG)			

1 [M] - - - - - [L T F L P P] - [P W A G I G R L I] - - - - - 999661
 1 [M] P L H V K W P P P A V [F P] L T W [T] L A S S V V M G L V G T GI 1263110

17 - - - - - 999661
 31 Y S C F W T K Y M N H L T V H N R E V L Y E L I E K R G P A GI 1263110

17 - - - - - [A E C H I L N P I] - - - [I L P L W H V] - - 999661
 61 T P L I T V S N H Q S [C M D D P] [P] H L W G I [L] K [R] H I W N L GI 1263110

32 - - - - - 999661
 91 K L M R W T P A A A D I C F T K E L H S H F F S L G K C V P GI 1263110

32 - - - - - 999661
 121 V C R G A E F F Q A E N E G K G V L D T G R H M [P] G A [G] K R GI 1263110

40 - - - - - 999661
 151 R E K G D [G] V Y Q K [G] M D F I L E K L N H G D W V H I F P E GI 1263110

51 - - - - - 999661
 181 G K V N M S S E F L R F K W G I G R [L] I A E [C] H L N [P] I T L GI 1263110

64 - - - - - 999661
 211 P S V H C A A G M N D V L F N S P P Y F P R F G Q K I T V L GI 1263110

211 P L W [H] - - V I G M N D V L F N S P P Y F P R F G Q K I T V L GI 1263110

(57) Abstract

The invention provides human cell signaling proteins (CSIG) and polynucleotides which identify and encode CSIG. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of CSIG.

Incite Pharmaceuticals, Inc.
Patent Department
1211 Geneva 20

PATENT COOPERATION TREATY

JAN 26 2000

PCT

NOTIFICATION RELATING TO PRIORITY CLAIM

(PCT Rules 26bis.1 and 26bis.2 and
Administrative Instructions, Sections 402 and 409)

From the INTERNATIONAL BUREAU

To:

BILLINGS, Lucy, J.
Incite Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, CA 94304
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 23 December 1999 (23.12.99)	
Applicant's or agent's file reference PF-0572 PCT	IMPORTANT NOTIFICATION
International application No. PCT/US99/19072	International filing date (day/month/year) 19 August 1999 (19.08.99)
Applicant INCYTE PHARMACEUTICALS, INC. et al	

The applicant is hereby notified of the following in respect of the priority claim(s) made in the international application.

1. Correction of priority claim. In accordance with the applicant's notice received on: 07 December 1999 (07.12.99), the following priority claim has been corrected to read as follows:
US 21 August 1998 (21.08.98) 60/150,689
 - even though the indication of the number of the earlier application is missing.
 - even though the following indication in the priority claim is not the same as the corresponding indication appearing in the priority document:
2. Addition of priority claim. In accordance with the applicant's notice received on: , the following priority claim has been added:
 - even though the indication of the number of the earlier application is missing.
 - even though the following indication in the priority claim is not the same as the corresponding indication appearing in the priority document:
3. As a result of the correction and/or addition of (a) priority claim(s) under items 1 and/or 2, the (earliest) priority date is:
4. Priority claim considered not to have been made.
 - The applicant failed to respond to the invitation under Rule 26bis.2(a) (Form PCT/I/B/316) within the prescribed time limit.
 - The applicant's notice was received after the expiration of the prescribed time limit under Rule 26bis.1(a).
 - The applicant's notice failed to correct the priority claim so as to comply with the requirements of Rule 4.10.

The applicant may, before the technical preparations for international publication have been completed and subject to the payment of a fee, request the International Bureau to publish, together with the international application, information concerning the priority claim. See Rule 26bis.2(c) and the PCT Applicant's Guide, Volume I, Annex B2(IB).
5. In case where multiple priorities have been claimed, the above item(s) relate to the following priority claim(s):

US 21 August 1998 (21.08.98) 60/150,689 (item 2)
6. A copy of this notification has been sent to the receiving Office and
 - to the International Searching Authority (where the international search report has not yet been issued).
 - the designated Offices (which have already been notified of the receipt of the record copy).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Margret Fourné-Godbersen Telephone No. (41-21) 338 83 38 
---	--

PATENT COOPERATION TREATY

PCTNOTIFICATION OF WITHDRAWAL
OF PRIORITY CLAIM(PCT Rule 90bis.3 and
Administrative Instructions, Section 415(a) and (b))

From the INTERNATIONAL BUREAU

To:

BILLINGS, Lucy, J.
 Incyte Pharmaceuticals, Inc.
 3174 Porter Drive
 Palo Alto, CA 94304
 ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 23 December 1999 (23.12.99)	
Applicant's or agent's file reference PF-0572 PCT	IMPORTANT NOTIFICATION
International application No. PCT/US99/19072	International filing date (day/month/year) 19 August 1999 (19.08.99)
Applicant INCYTE PHARMACEUTICALS, INC.	

1. The applicant is hereby notified that the priority claim made in the international application has been withdrawn in accordance with a notice of withdrawal received from the applicant on:

07 December 1999 (07.12.99)

The attention of the applicant is drawn to the fact that the withdrawal of the priority claim will result in the re-calculation of time limits which have not already expired (see Rule 90bis.3(d)).

2. In the case where multiple priorities have been claimed, the above action relates to the following priority claim(s):

US	09/137,945	21 August 1998 (21.08.98)
----	------------	---------------------------

3. A copy of this notification has been sent to the receiving Office and to:

- the International Searching Authority (*where the international search report has not yet been issued*)
- the designated Offices (*which have already been notified of the receipt of the record copy*)
- the International Preliminary Examining Authority